Corporate digest
Star Pharmaceutical
THE independent financial adviser (IFA) of mainboard-listed Star Pharmaceutical said on Tuesday that the offer price of S$0.45 a share is "fair and reasonable". The independent directors agreed with the advice and recommendations of the IFA CEL Impetus Corporate Finance and recommended that shareholders accept the offer.
This comes as the offer price represents a premium of about 180 per cent, 176 per cent, 187 per cent and 192 per cent over the volume-weighted average price per share for the one-month, three-month, six-month and 12-month periods respectively.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
TikTok tells advertisers: ‘We are not backing down’
EV automakers get reprieve in US tax credit rules
Nomura, Mizuho face losses on All Blue fund’s failed trades
Stablecoin Tether steps up monitoring in bid to combat illicit finance
HSBC asked by US$890 billion investor group to set energy goal
BHP’s biggest rivals sit on the sidelines of Anglo M&A drama